Financial Toxicity Common in Patients With Multiple Myeloma

Share this content:
Due to the use of novel therapies and treatment duration, patients with multiple myeloma are more vulnerable to financial toxicity.
Due to the use of novel therapies and treatment duration, patients with multiple myeloma are more vulnerable to financial toxicity.

Financial toxicity is increasingly affecting patient quality of life and medication adherence in patients with cancer. Due to the use of novel therapies and the need for extended treatment duration, patients with multiple myeloma are more vulnerable to it.1

Patient-reported financial toxicity was common in an insured population with multiple myeloma, according to a study published online ahead of print in The Lancet Haematology.

Researchers performed a cross-sectional survey of 100 individuals receiving at least 3 months of ongoing treatment for multiple myeloma at a tertiary academic cancer center in the United States. It included the 11-item COST measure (financial toxicity score range 0 to 44).

Eligible patients were given a paper survey to complete on arrival for routine follow-up visits, and were asked to finish it before or after the visit. Insurance and treatment data were gathered from the patients' electronic health records.

Results showed that 59% of patients reported that treatment costs were higher than expected, 70% of patients had at least minor financial burden, 36% applied for financial assistance, and 21% of patients borrowed money to pay for medications. COST scores were correlated with patient-reported use of strategies to cope with myeloma treatment expenses.

RELATED: EMC92-ISS Superior to Other Current Markers in Risk Classification for Myeloma Survival

On multivariable analysis, younger age (correlation coefficient β: 0.36; 95% CI: 0.15 to 0.56; P=0.00092), non-married status (correlation coefficient β: 5.6; 95% CI: 1.5 to 9.6; P=0.0074), longer duration since diagnosis (correlation coefficient β: −4.8, 95% CI: −9·3 to −0·2; P=0.042), and lower household income ($40,000–79,999; correlation coefficient β: 7.8, 95% CI: 2.7 to 12.9; P=0.0031; ≥$80 000: correlation coefficient β: 11.8; 95% CI: 7.1 to 16·4; P<0.0001) were associated with higher financial burden as measured with the COST score.

Researchers concluded that additional attention should be paid to rising treatment costs and cost sharing is needed to address the increasing financial toxicity affecting patients with cancer.

Reference

  1. Huntington SF, Weiss B, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. [published ahead of print September 17, 2015]. Lancet Haematol. doi: 10.1016/S2352-3026(15)00151-9.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs